RNA-seq characterization of histamine-releasing mast cells as potential therapeutic target of osteoarthritis.

Objective: Mast cells in the osteoarthritis (OA) synovium correlate with disease severity. This study aimed to further elucidate the role of mast cells in OA by RNA-Seq analysis and pharmacological blockade of the activity of histamine, a key mast cell mediator, in murine OA.
Methods: We examined OA synovial tissues and fluids by flow cytometry, immunostaining, single-cell and bulk RNA-Seq, qPCR, and ELISA. Cetirizine, a histamine H1 receptor (H ₁ R) antagonist, was used to treat the destabilization of the medial meniscus (DMM) mouse model of OA.
Results: Flow cytometry and immunohistology analysis of OA synovial cells revealed KIT ⁺ FcεRI ⁺ and TPSAB1 ⁺ mast cells. Single-cell RNA-Seq of OA synovial cells identified the expression of prototypical mast cell markers KIT, TPSAB1, CPA3 and HDC, as well as distinctive markers HPGD, CAVIN2, IL1RL1, PRG2, and CKLF, confirmed by bulk RNA-Seq and qPCR. A mast cell prototypical marker expression score classified 40 OA patients into three synovial pathotypes: mast cell-high, -medium, and -low. Additionally, we detected mast cell mediators including histamine, tryptase AB1, CPA3, PRG2, CAVIN2, and CKLF in OA synovial fluids. Elevated H ₁ R expression was detected in human OA synovium, and treatment of mice with the H ₁ receptor antagonist cetirizine reduced the severity and OA-related mediators in DMM.
Conclusion: Based on differential expression of prototypical and distinct mast cell markers, human OA joints can be stratified into mast cell-high, -medium, and -low synovial tissue pathotypes. Pharmacologic blockade of histamine activity holds the potential to improve OA disease outcome.
Competing Interests: Declaration of Competing Interest The authors declare no conflicts of interest.
(Copyright © 2022. Published by Elsevier Inc.)